Ultragenyx Pharmaceutical Obtains $121,000,000 New Financing

  • Feed Type
  • Date
    1/31/2014
  • Company Name
    Ultragenyx Pharmaceutical
  • Mailing Address
    60 Leveroni Court Novato, CA 94949
  • Company Description
    Ultragenyx (NASDAQ: RARE) is focused on developing therapeutics for rare diseases. The company will build on management’s experience in choosing and developing products with clear mechanisms of action in untreated rare diseases.
  • Website
    http://www.ultragenyx.com
  • Transaction Type
    IPO
  • Transaction Amount
    $121,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes are on file with company statements at the SEC.
  • M&A Terms

By posting a comment, you agree to our terms and conditions.